Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 288, Issue 6 32-6, 2005, Pages

  Wang, Zhengdong ^a   Foye, Adam ^a   Chang, Yusuo ^a   Chess, Patricia R ^a   Wright, Terry W ^a   Bhagwat, Samir ^a   Gigliotti, Francis ^a   Notter, Robert H ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Lung injury; Lung surfactant; Surfactant dysfunction

Indexed keywords

LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; PHOSPHOLIPID; SURFACTANT PROTEIN A; UNCLASSIFIED DRUG; WHOLE CALF LUNG SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYDROPHOBICITY; INHIBITION KINETICS; LUNG ALVEOLUS SURFACE TENSION; LUNG INJURY; MICROBIAL ACTIVITY; MOUSE; NONHUMAN; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

ANIMALS; CATTLE; LUNG; MICE; MICE, SCID; PHOSPHOLIPIDS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANTS; SURFACE TENSION;

EID: 18844420233     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00453.2004     Document Type: Article

References (58)

1. Ames BN. Assay of inorganic phosphate, total phosphate and phosphatases. Methods Enzymol 8: 115-118, 1966.
2. Atochina EN, Beers MF, Scanlon ST, Preston AM, and Beck JM. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol Lung Cell Mol Physiol 278: L599-L609, 2000.
3. Auten RL, Notter RH, Kendig JW, Davis JM, and Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87: 101-107, 1991.
4. Beers MF, Atochina EN, Preston AM, and Beck JM. Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice. J Lab Clin Med 133: 423-433, 1999.
5. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, and Spragg R. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149: 818-824, 1994.
6. Bligh EG and Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
7. Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, Wagner JL, Witherspoon RP, Anasetti C, Appelbaum FR, Bensinger WI, Deeg HJ, Martin PJ, Sanders JE, Storb R, Storek J, Wade J, Siadak M, Flowers ME, and Sullivan KM. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 32: 515-522, 2003.
8. Cockshutt A and Possmayer F. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by plasma proteins. Biochim Biophys Acta 1086: 63-71, 1991.
9. Cockshutt AM, Weitz J, and Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 19: 8424-8429, 1990.
10. Dei-Cas E. Pneumocystis infections: the tip of the iceberg? Med Mycol 38, Suppl 1: 23-32, 2000.
11. Enhorning G. Pulsating bubble technique for evaluation of pulmonary surfactant. J Appl Physiol 43: 198-203, 1977.
12. Escamilla R, Prevost MC, Cariven C, Hermant C, Krempf M, and Chap H. Bronchoalveolar lavage phospholipid abnormalities in HIV-infected patients. Eur Respir J 6: 1301-1307, 1993.
13. Guo Z, Beach DH, and Kaneshiro ES. Fatty acid composition of the major phospholipids of Pneumocystic carinii: comparison with those in the lungs of normal and methylprednisolone-immunosuppressed rats. Infect Immun 64: 1407-1412, 1996.
14. Guo Z and Kaneshiro ES. Phospholipid composition of Pneumocystis carinii carinii and effects of methylprednisolone immunosuppression on rat lung lipids. Infect Immun 63: 1286-1290, 1995.
15. Hall SB, Bermel MS, Ko YT, Palmer HJ, Enhorning GA, and Notter RH. Approximations in the measurement of surface tension with the oscillating bubble surfactometer. J Appl Physiol 75: 468-477, 1993.
16. Hall SB, Hyde RW, and Notter RH. Changes in subphase surfactant aggregates in rabbits injured by free fatty acid. Am J Respir Crit Care Med 149: 1099-1106, 1994.
17. Hall SB, Lu ZR, Venkitaraman AR, Hyde RW, and Notter RH. Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics. J Appl Physiol 72: 1708-1716, 1992.
18. Hoffman AG, Lawrence MG, Ognibene FP, Suffredini AF, Lipschik GY, Kovacs JA, Masur H, and Shelhamer JH. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and P. carinii pneumonia. Chest 102: 1730-1736, 1992.
19. Holm BA and Notter RH. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 63: 1434-1442, 1987.
20. Holm BA, Wang Z, and Notter RH. Multiple mechanisms of lung surfactant inhibition. Pediatr Res 46: 85-93, 1999.
21. Kaneshiro ES, Ellis JE, Guo Z, Jayasimhulu K, Maiorano JN, and Kallam KA. Characterizations of neutral lipid fatty acids and cis-9,10-epoxy octadecanoic acid in Pneumocystis carinii. Infect Immun 64: 4105-4114, 1996.
22. Lee LH, Gigliotti F, Wright TW, Simpson-Haidaris PJ, Weinberg GA, and Haidaris CG. Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii. Gene 242: 141-150, 2000.
23. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 132: 265-275, 1951.
24. Mandell GL, Bennett JE, and Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 2000.
25. Mansharamani NG, Garland R, Delaney D, and Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985-1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118: 704-711, 2000.
26. Martin WJ and Wright JR. Pneumocystis carinii pneumonia and pulmonary surfactant. J Lab Clin Med 133: 406-407, 1999.
27. McAllister F, Steele C, Zheng M, Young E, Shellito JE, Marrero L, and Kolls JK. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol 172: 1132-1138, 2004.
28. McCormack FX, Festa AL, Andrews RP, Linke MJ, and Walzer PD. The carbohydrate recognition domain of surfactant protein A mediates binding to the major surface glycoprotein of P. carinii. Biochemistry 36: 8092-8099, 1997.
29. Merigan TC, Bartlett JG, and Bolognesi D (Editors). AIDS Medicine. New York: Williams and Wilkins, 1999.
30. Notter RH. Lung Surfactants: Basic Science and Clinical Applications. New York: Dekker, 2000.
31. Notter RH, Apostolakos M, Holm BA, Willson D, Wang Z, Finkelstein JN, and Hyde RW. Surfactant therapy and its potential use with other agents in term infants, children and adults with acute lung injury. Perspect Neonatal 1: 4-20, 2000.
32. Notter RH, Penney DP, Finkelstein JN, and Shapiro DL. Adsorption of natural lung surfactant and phospholipid extracts related to tubular myelin formation. Pediatr Res 20: 97-101, 1986.
33. Notter RH, Tabak SA, and Mavis RD. Surface properties of binary mixtures of some pulmonary surfactant components. J Lipid Res 21: 10-22, 1980.
34. Notter RH and Wang Z. Pulmonary surfactant: physical chemistry, physiology and replacement. Rev Chem Eng 13: 1-118, 1997.
35. Notter RH, Wang Z, Egan EA, and Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 114: 21-34, 2002.
36. O'Riordan DM, Standing JE, Kwon KY, Chang D, Crouch EC, and Limper AH. Surfactant protein D interacts with P. carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 95: 2699-2710, 1995.
37. Paulsrud JR, Queener SF, Bartlett MS, and Smith JW. Total cellular fatty acid composition of cultured Pneumocystis carinii. J Clin Microbiol 31: 1899-1902, 1993.
38. Pesanti EL. Phospholipid profile of Pneumocystis carinii and its interaction with alveolar type II epithelial cells. Infect Immun 55: 736-741, 1987.
39. Phelps DS and Rose RM. Increased recovery of surfactant protein A in AIDS-related pneumonia. Am Rev Respir Dis 143: 1072-1075, 1991.
40. Phelps DS, Unstead TM, Rose RM, and Fishman JA. Surfactant protein-A levels increase during P. carinii pneumonia in the rat. Eur Respir J 9: 565-570, 1996.
41. Roblot F, Le Moal G, Godet C, Hutin P, Texereau M, Boyer E, Prazuck T, Lacroix C, Souala MF, Raffi F, Weinbreck P, Besnier JM, Garo B, de Gentile L, and Becq-Giraudon B. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect 47: 19-27, 2003.
42. Rose RM, Catalano PJ, Koziel H, and Furlong ST. Abnormal lipid composition of bronchoalveolar fluid obtained from individuals with AIDS-related lung disease. Am J Respir Crit Care Med 149: 332-338, 1994.
43. Searcy RL and Bergquist LM. A new color reaction for the quantitation of serum cholesterol. Clin Chim Acta 5: 192-199, 1960.
44. Seeger W, Günther A, Walmrath HD, Grimminger F, and Lasch HG. Alveolar surfactant and adult respiratory distress syndrome. Pathogenic role and therapeutic prospects. Clin Invest 71: 177-190, 1993.
45. 2 in experimental Pneumocystis carinii pneumonia. Am Rev Respir Dis 134: 526-531, 1986.
46. Sternberg RI, Whitsett JA, Hull WM, and Baughman RP. P. carinii alters surfactant protein A concentration in bronchoalveolar lavage fluid. J Lab Clin Med 125: 462-469, 1995.
47. Su TH and Martin WJ. Pathogenesis and host response in Pneumocystis carinii pneumonia. Annu Rev Med 45: 261-272, 1994.
48. Su TH, Natarajan V, Kachel BL, Moxley MA, Longmore WJ, and Martin WJ. Functional impairment of bronchoalveolar lavage phospholipids in early P. carinii pneumonia in rats. J Lab Clin Med 127: 263-271, 1996.
49. Tierney DF and Johnson RP. Altered surface tension of lung extracts and lung mechanics. J Appl Physiol 20: 1253-1260, 1965.
50. Touchstone JC, Chen JC, and Beaver KM. Improved separation of phospholipids in thin-layer chromatography. Lipids 15: 61-62, 1980.
51. Wang Z, Gurel O, Weinbach S, and Notter RH. Primary importance of zwitterionic over anionic phospholipids in the surface active function of calf lung surfactant extract. Am J Respir Crit Care Med 156: 1049-1057, 1997.
52. Wang Z and Notter RH. Additivity of protein and non-protein inhibitors of lung surfactant activity. Am J Respir Crit Care Med 158: 28-35, 1998.
53. Wang Z, Schwan AL, Lairson LL, O'Donnell JS, Byrne GF, Foye A, Holm BA, and Notter RH. Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine. Am J Physiol Lung Cell Mol Physiol 285: L550-L559, 2003.
54. Willson DF, Bauman LA, Zaritsky A, Dockery K, James RL, Stat M, Conrad D, Craft H, Novotny WE, Egan EA, and Dalton H. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med 27: 188-195, 1999.
55. Willson DF, Jiao JH, Bauman LA, Zaritsky A, Craft H, Dockery K, Conrad D, and Dalton H. Calf lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 24: 1316-1322, 1996.
56. Wright TW, Notter RH, Wang Z, Harmsen AG, and Gigliotti F. Pulmonary inflammation disrupts surfactant function during P. carinii pneumonia. Infect Immun 69: 758-764, 2001.
57. Wright TW, Pryhuber G, Chess P, Wang Z, Notter RH, and Gigliotti F. TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during pneumocystis pneumonia. J Immunol 172: 2511-2521, 2004.
58. Zimmerman PE, Voelker DR, McCormack FX, Paulsrud JR, and Martin WJ. 120-kD surface glycoprotein of P. carinii is a ligand for surfactant protein A. J Clin Invest 89: 143-149, 1992.